CA2797694A1 - Activators of human pyruvate kinase - Google Patents
Activators of human pyruvate kinase Download PDFInfo
- Publication number
- CA2797694A1 CA2797694A1 CA2797694A CA2797694A CA2797694A1 CA 2797694 A1 CA2797694 A1 CA 2797694A1 CA 2797694 A CA2797694 A CA 2797694A CA 2797694 A CA2797694 A CA 2797694A CA 2797694 A1 CA2797694 A1 CA 2797694A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- oxo
- sulfonamide
- alkyl
- tetrahydroquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000013009 Pyruvate Kinase Human genes 0.000 title abstract 2
- 108020005115 Pyruvate Kinase Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract 25
- 201000011510 cancer Diseases 0.000 claims abstract 25
- 230000004913 activation Effects 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- -1 (C1-C4)alkyl-CO- Chemical group 0.000 claims 73
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000004122 cyclic group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical group O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 201000009047 Chordoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 2
- 206010046392 Ureteric cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 208000004064 acoustic neuroma Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 2
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims 2
- 210000002255 anal canal Anatomy 0.000 claims 2
- 201000007180 bile duct carcinoma Diseases 0.000 claims 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000024207 chronic leukemia Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 2
- 210000000959 ear middle Anatomy 0.000 claims 2
- 208000037828 epithelial carcinoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000025750 heavy chain disease Diseases 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 201000004962 larynx cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims 2
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 claims 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 210000000713 mesentery Anatomy 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000001611 myxosarcoma Diseases 0.000 claims 2
- 210000003928 nasal cavity Anatomy 0.000 claims 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 2
- 208000007538 neurilemmoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 210000002747 omentum Anatomy 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 2
- 201000010198 papillary carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 201000008006 pharynx cancer Diseases 0.000 claims 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims 2
- 201000004123 pineal gland cancer Diseases 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 201000003437 pleural cancer Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 2
- 206010042863 synovial sarcoma Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000011294 ureter cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- XESJSVKSJFRHPE-UHFFFAOYSA-N 1-acetyl-n-(3,4-dimethylphenyl)-2,3-dihydroindole-5-sulfonamide Chemical compound C=1C=C2N(C(=O)C)CCC2=CC=1S(=O)(=O)NC1=CC=C(C)C(C)=C1 XESJSVKSJFRHPE-UHFFFAOYSA-N 0.000 claims 1
- KUMQIRFCKBSETE-UHFFFAOYSA-N 1-acetyl-n-(3,4-dimethylphenyl)-2-methyl-2,3-dihydroindole-5-sulfonamide Chemical compound C=1C=C2N(C(C)=O)C(C)CC2=CC=1S(=O)(=O)NC1=CC=C(C)C(C)=C1 KUMQIRFCKBSETE-UHFFFAOYSA-N 0.000 claims 1
- WVMOGAPSTDCYRO-UHFFFAOYSA-N 2-oxo-n-(3-phenylphenyl)-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 WVMOGAPSTDCYRO-UHFFFAOYSA-N 0.000 claims 1
- WQRPZEZBGHLTAC-UHFFFAOYSA-N 2-oxo-n-[3-(trifluoromethyl)phenyl]-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC(F)(F)C1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 WQRPZEZBGHLTAC-UHFFFAOYSA-N 0.000 claims 1
- DWLBYLGNERHAIR-UHFFFAOYSA-N 2-oxo-n-pyridin-3-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC1=CC=CN=C1 DWLBYLGNERHAIR-UHFFFAOYSA-N 0.000 claims 1
- ICWKDRRYYPUARX-UHFFFAOYSA-N 3,3-dichloro-n-(3,4-dimethylphenyl)-2-oxo-1h-indole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)C2(Cl)Cl)C2=C1 ICWKDRRYYPUARX-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- PNUCPERAJKCNDW-UHFFFAOYSA-N 6-(dimethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CN(C)C1=CC=2CCC(=O)NC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 PNUCPERAJKCNDW-UHFFFAOYSA-N 0.000 claims 1
- UKDWCJDLGFLUDX-UHFFFAOYSA-N 6-bromo-N-(3,4-dimethylphenyl)-3-oxo-4H-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Br)=CC2=C1NC(=O)CO2 UKDWCJDLGFLUDX-UHFFFAOYSA-N 0.000 claims 1
- CENVPIZOTHULGJ-UHFFFAOYSA-N 6-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=C2CC(=O)NC2=C1 CENVPIZOTHULGJ-UHFFFAOYSA-N 0.000 claims 1
- NLCUMMKSKTZTBQ-UHFFFAOYSA-N 6-chloro-N-(3,4-dimethylphenyl)-3-oxo-4H-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(=O)CO2 NLCUMMKSKTZTBQ-UHFFFAOYSA-N 0.000 claims 1
- XRRWVAJHXHPVMF-UHFFFAOYSA-N 6-chloro-n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(=O)C2 XRRWVAJHXHPVMF-UHFFFAOYSA-N 0.000 claims 1
- YGLBSBMBNJMIQH-UHFFFAOYSA-N 6-chloro-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 YGLBSBMBNJMIQH-UHFFFAOYSA-N 0.000 claims 1
- XRNQVMXHJDERIT-UHFFFAOYSA-N 6-chloro-n-(3-chloro-2-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CC1=C(Cl)C=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 XRNQVMXHJDERIT-UHFFFAOYSA-N 0.000 claims 1
- RFVFXQILUXVPQU-UHFFFAOYSA-N 6-chloro-n-(3-chloro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 RFVFXQILUXVPQU-UHFFFAOYSA-N 0.000 claims 1
- KEEWNCGXRMKJTQ-UHFFFAOYSA-N 6-chloro-n-(5-chloro-2-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CC1=CC=C(Cl)C=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 KEEWNCGXRMKJTQ-UHFFFAOYSA-N 0.000 claims 1
- CPCRMUCDKAAXGT-UHFFFAOYSA-N 7-(diethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CCN(CC)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CPCRMUCDKAAXGT-UHFFFAOYSA-N 0.000 claims 1
- JTMUYMFTDPYETO-UHFFFAOYSA-N 7-(dimethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CN(C)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 JTMUYMFTDPYETO-UHFFFAOYSA-N 0.000 claims 1
- AOEUWFASGTXXAQ-UHFFFAOYSA-N 7-[2-(dimethylamino)ethyl-methylamino]-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CN(C)CCN(C)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 AOEUWFASGTXXAQ-UHFFFAOYSA-N 0.000 claims 1
- NFXGFWJXAFTFGK-UHFFFAOYSA-N 7-[3-(dimethylamino)pyrrolidin-1-yl]-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1C(N(C)C)CCN1C(C(=C1)S(=O)(=O)NC=2C=C(C)C(C)=CC=2)=CC2=C1CCC(=O)N2 NFXGFWJXAFTFGK-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- JPRSMOUDRVVIHR-UHFFFAOYSA-N N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound O1CCOC2=CC(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=C21 JPRSMOUDRVVIHR-UHFFFAOYSA-N 0.000 claims 1
- IRRZNGIKUYWLLJ-UHFFFAOYSA-N N-(2-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 IRRZNGIKUYWLLJ-UHFFFAOYSA-N 0.000 claims 1
- SNFROMRRGGKYTF-UHFFFAOYSA-N N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 SNFROMRRGGKYTF-UHFFFAOYSA-N 0.000 claims 1
- KQHKZXBKJWOHHU-UHFFFAOYSA-N N-(3-chlorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound ClC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 KQHKZXBKJWOHHU-UHFFFAOYSA-N 0.000 claims 1
- FVLSXGNSQKPXJN-UHFFFAOYSA-N N-(3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound CC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 FVLSXGNSQKPXJN-UHFFFAOYSA-N 0.000 claims 1
- GTFOCOKDGPLBEK-UHFFFAOYSA-N N-(4-chloro-3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 GTFOCOKDGPLBEK-UHFFFAOYSA-N 0.000 claims 1
- BANOCBYMYBHZCK-UHFFFAOYSA-N N-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=CC(F)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 BANOCBYMYBHZCK-UHFFFAOYSA-N 0.000 claims 1
- YIKOTMZSQQKCNN-UHFFFAOYSA-N N-(4-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=CC(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 YIKOTMZSQQKCNN-UHFFFAOYSA-N 0.000 claims 1
- AIEOBFOLWRLWFY-UHFFFAOYSA-N [3-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)sulfonylamino]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 AIEOBFOLWRLWFY-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- FXULHVBWXADQIT-UHFFFAOYSA-N n-(2-fluorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 FXULHVBWXADQIT-UHFFFAOYSA-N 0.000 claims 1
- HPTNHSMTBSTARS-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 HPTNHSMTBSTARS-UHFFFAOYSA-N 0.000 claims 1
- WDMSYXZEYIVUAV-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 WDMSYXZEYIVUAV-UHFFFAOYSA-N 0.000 claims 1
- TVEWYQNBFLBJON-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(Cl)C(Cl)=C1 TVEWYQNBFLBJON-UHFFFAOYSA-N 0.000 claims 1
- OZCHLLBJIJDZSV-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-1,3-dimethyl-2-oxobenzimidazole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(N(C)C(=O)N2C)C2=C1 OZCHLLBJIJDZSV-UHFFFAOYSA-N 0.000 claims 1
- PQRJAXXCZAABJD-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-1-methylindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(N(C)C=C2)C2=C1 PQRJAXXCZAABJD-UHFFFAOYSA-N 0.000 claims 1
- CKACPEDULOKSHJ-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3,4,5-tetrahydro-1-benzazepine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CCC2)C2=C1 CKACPEDULOKSHJ-UHFFFAOYSA-N 0.000 claims 1
- BSEGVWNGGVEPQX-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydrobenzimidazole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)N2)C2=C1 BSEGVWNGGVEPQX-UHFFFAOYSA-N 0.000 claims 1
- XMTTXQUJUKTALG-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)C2)C2=C1 XMTTXQUJUKTALG-UHFFFAOYSA-N 0.000 claims 1
- ABPIVUMUUZSCTQ-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-carboxamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=CC=C(NC(=O)CC2)C2=C1 ABPIVUMUUZSCTQ-UHFFFAOYSA-N 0.000 claims 1
- CAPFLYHFMYQPBI-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-(propan-2-ylamino)-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CC(C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CAPFLYHFMYQPBI-UHFFFAOYSA-N 0.000 claims 1
- PFQAFZFSUCEPGW-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-piperidin-1-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)N2CCCCC2)=CC2=C1NC(=O)CC2 PFQAFZFSUCEPGW-UHFFFAOYSA-N 0.000 claims 1
- ZMERFADMZRTONY-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-pyrrolidin-1-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)N2CCCC2)=CC2=C1NC(=O)CC2 ZMERFADMZRTONY-UHFFFAOYSA-N 0.000 claims 1
- FLRPVXLMOJGRDV-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-3-oxo-4h-1,4-benzoxazine-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(OCC(=O)N2)C2=C1 FLRPVXLMOJGRDV-UHFFFAOYSA-N 0.000 claims 1
- LFKHSAHGVHJEPF-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-3-oxo-6-phenyl-4h-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)C=2C=CC=CC=2)=CC2=C1NC(=O)CO2 LFKHSAHGVHJEPF-UHFFFAOYSA-N 0.000 claims 1
- CRZDZXNDKULTHH-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-4-methyl-3-oxo-1,4-benzoxazine-6-sulfonamide Chemical compound C1=C2N(C)C(=O)COC2=CC=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CRZDZXNDKULTHH-UHFFFAOYSA-N 0.000 claims 1
- OHQSSKLYMQFLQN-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-6-methyl-3-oxo-4h-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)C)=CC2=C1NC(=O)CO2 OHQSSKLYMQFLQN-UHFFFAOYSA-N 0.000 claims 1
- FTLNYBCPHCLODH-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(1-hydroxypropan-2-ylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OCC(C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-UHFFFAOYSA-N 0.000 claims 1
- WQEYRSZNQWSCKO-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(2-hydroxyethylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)NCCO)=CC2=C1NC(=O)CC2 WQEYRSZNQWSCKO-UHFFFAOYSA-N 0.000 claims 1
- RDJVVXIZIXTZEL-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(methylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CNC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 RDJVVXIZIXTZEL-UHFFFAOYSA-N 0.000 claims 1
- IAJXECZPLGLEKB-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-[(2-hydroxy-2-methylpropyl)amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)NCC(C)(C)O)=CC2=C1NC(=O)CC2 IAJXECZPLGLEKB-UHFFFAOYSA-N 0.000 claims 1
- FTLNYBCPHCLODH-CQSZACIVSA-N n-(3,4-dimethylphenyl)-7-[[(2r)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-CQSZACIVSA-N 0.000 claims 1
- FTLNYBCPHCLODH-AWEZNQCLSA-N n-(3,4-dimethylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-AWEZNQCLSA-N 0.000 claims 1
- MSHCFYZEHSRAPG-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 MSHCFYZEHSRAPG-UHFFFAOYSA-N 0.000 claims 1
- QITDSYIYIPIMLL-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-n-methyl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)N(C)C1=CC=C(C)C(C)=C1 QITDSYIYIPIMLL-UHFFFAOYSA-N 0.000 claims 1
- HOPSYFZHYRZZBT-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CC1=C(Cl)C=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 HOPSYFZHYRZZBT-UHFFFAOYSA-N 0.000 claims 1
- CUZDABRLLGGXKI-JTQLQIEISA-N n-(3-chloro-4-fluorophenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(F)C(Cl)=C1 CUZDABRLLGGXKI-JTQLQIEISA-N 0.000 claims 1
- NRHQXXODPRXAER-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 NRHQXXODPRXAER-UHFFFAOYSA-N 0.000 claims 1
- VLRYVDZPCCVRIS-LBPRGKRZSA-N n-(3-chloro-4-methylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(Cl)=C1 VLRYVDZPCCVRIS-LBPRGKRZSA-N 0.000 claims 1
- HYOLJEHGMOJMNR-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 HYOLJEHGMOJMNR-UHFFFAOYSA-N 0.000 claims 1
- NQPXVAUSZJKKDP-UHFFFAOYSA-N n-(3-cyanophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC1=CC=CC(C#N)=C1 NQPXVAUSZJKKDP-UHFFFAOYSA-N 0.000 claims 1
- YBQWWIYDCVJQAW-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(F)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 YBQWWIYDCVJQAW-UHFFFAOYSA-N 0.000 claims 1
- CBBKJQADPAHXLO-UHFFFAOYSA-N n-(3-fluorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 CBBKJQADPAHXLO-UHFFFAOYSA-N 0.000 claims 1
- IZMRNRGXIQXSKA-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 IZMRNRGXIQXSKA-UHFFFAOYSA-N 0.000 claims 1
- FGSXPFIJRVGTDM-UHFFFAOYSA-N n-(4-chloro-3-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC(NS(=O)(=O)C=2C(=CC=3NC(=O)CCC=3C=2)F)=C1 FGSXPFIJRVGTDM-UHFFFAOYSA-N 0.000 claims 1
- AISVTQYDRIQDKU-UHFFFAOYSA-N n-(4-chlorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC(Cl)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 AISVTQYDRIQDKU-UHFFFAOYSA-N 0.000 claims 1
- LPVLUUBCUWKBJT-UHFFFAOYSA-N n-(4-fluoro-3-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(F)C(C)=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 LPVLUUBCUWKBJT-UHFFFAOYSA-N 0.000 claims 1
- SLPTYIRATHEPAX-LBPRGKRZSA-N n-(4-fluoro-3-methylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(F)C(C)=C1 SLPTYIRATHEPAX-LBPRGKRZSA-N 0.000 claims 1
- AEYRWLQXGYDIOE-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 AEYRWLQXGYDIOE-UHFFFAOYSA-N 0.000 claims 1
- RZCXGKSKBPHLSG-UHFFFAOYSA-N n-(5-chloro-2-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CC1=CC=C(Cl)C=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 RZCXGKSKBPHLSG-UHFFFAOYSA-N 0.000 claims 1
- OCVBNKSYCFRIMO-UHFFFAOYSA-N n-benzyl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NCC1=CC=CC=C1 OCVBNKSYCFRIMO-UHFFFAOYSA-N 0.000 claims 1
- OZKITVZVEHPSNT-UHFFFAOYSA-N n-naphthalen-1-yl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC=C2C(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=CC2=C1 OZKITVZVEHPSNT-UHFFFAOYSA-N 0.000 claims 1
- DVUSSGILUNAHHB-UHFFFAOYSA-N n-naphthalen-2-yl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC=CC2=CC(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=C21 DVUSSGILUNAHHB-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 abstract 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32915810P | 2010-04-29 | 2010-04-29 | |
| US61/329,158 | 2010-04-29 | ||
| PCT/US2011/033852 WO2011137089A1 (en) | 2010-04-29 | 2011-04-26 | Activators of human pyruvate kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2797694A1 true CA2797694A1 (en) | 2011-11-03 |
Family
ID=44280778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2797694A Abandoned CA2797694A1 (en) | 2010-04-29 | 2011-04-26 | Activators of human pyruvate kinase |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130109672A1 (enExample) |
| EP (1) | EP2563761A1 (enExample) |
| JP (1) | JP2013525438A (enExample) |
| AU (1) | AU2011245441B2 (enExample) |
| CA (1) | CA2797694A1 (enExample) |
| WO (1) | WO2011137089A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102448951B (zh) | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
| AR077292A1 (es) | 2009-06-29 | 2011-08-17 | Agios Pharmaceuticals Inc | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas |
| CA2766873C (en) | 2009-06-29 | 2018-08-21 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| EP2651898B1 (en) | 2010-12-17 | 2015-12-09 | Agios Pharmaceuticals, Inc. | Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| US9328077B2 (en) | 2010-12-21 | 2016-05-03 | Agios Pharmaceuticals, Inc | Bicyclic PKM2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| HUE065700T2 (hu) | 2011-05-03 | 2024-06-28 | Agios Pharmaceuticals Inc | Piruvát-kináz aktivátorok terápiában történõ alkalmazásra |
| WO2012151440A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| WO2013027168A1 (en) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| CN104822672B (zh) * | 2012-11-08 | 2018-08-28 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物以及其作为pkm2调节剂的用途 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CN105272904B (zh) * | 2014-07-18 | 2019-04-09 | 中国科学院广州生物医药与健康研究院 | N-苯基酰胺类化合物及其应用 |
| KR102633122B1 (ko) | 2014-08-01 | 2024-02-05 | 누에볼루션 에이/에스 | 브로모도메인에 대하여 활성을 갖는 화합물 |
| FR3030518B1 (fr) | 2014-12-19 | 2018-03-23 | Galderma Research & Development | Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| FR3030516B1 (fr) | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| PL3307271T3 (pl) | 2015-06-11 | 2024-02-05 | Agios Pharmaceuticals, Inc. | Sposoby stosowania aktywatorów kinazy pirogronianowej |
| US10626087B2 (en) | 2015-07-10 | 2020-04-21 | Loyola University Of Chicago | Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same |
| KR102007135B1 (ko) | 2017-03-20 | 2019-08-02 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
| SG11202001353PA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase modulators and use thereof |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019169267A1 (en) * | 2018-03-01 | 2019-09-06 | Reaction Biology Corp. | Quinoline and isoquinoline based hdac inhibitors and methods of use thereof |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| EP3986890B9 (en) | 2019-06-18 | 2025-04-16 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| DE102019129527A1 (de) | 2019-10-31 | 2021-05-06 | Forschungszentrum Jülich GmbH | Inhibitoren für Bromodomänen |
| US20240000806A1 (en) * | 2020-11-20 | 2024-01-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for inhibiting cb1 activity |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL80569C (enExample) * | 1949-07-23 | |||
| US3998828A (en) | 1975-01-31 | 1976-12-21 | Pfizer Inc. | 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS569749A (en) * | 1979-07-04 | 1981-01-31 | Mitsubishi Paper Mills Ltd | Preparation of lithographic plate |
| DE2948434A1 (de) | 1979-12-01 | 1981-06-11 | Hoechst Ag, 6000 Frankfurt | 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4593102A (en) | 1984-04-10 | 1986-06-03 | A. H. Robins Company, Inc. | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| JPH0667926B2 (ja) | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| BR9200951A (pt) | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
| IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
| US5891435A (en) | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| WO1996022287A1 (en) | 1995-01-20 | 1996-07-25 | G.D. Searle & Co. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
| JPH09286783A (ja) * | 1996-02-19 | 1997-11-04 | Fuji Photo Film Co Ltd | 感熱記録材料及びジアゾ化合物 |
| DE19629335A1 (de) | 1996-07-20 | 1998-01-22 | Golden Records Ass Internation | Karte aus Kunststoff |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| AR016384A1 (es) | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
| AR016551A1 (es) * | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| DE19755268A1 (de) * | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| EA200100882A1 (ru) | 1999-02-09 | 2002-04-25 | 3-Дименшенл Фамэсьютикэлс, Инк. | Гетероарильные производные амидина, метиламидина и гуанидина (варианты), способ их получения, фармацевтическая композиция (варианты), способ ингибирования протеазы (варианты) и способ лечения различных заболеваний (варианты) |
| US6211182B1 (en) | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
| CO5170498A1 (es) | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| JP2003510278A (ja) | 1999-09-30 | 2003-03-18 | スミスクライン・ビーチャム・コーポレイション | カスパーゼおよびアポプトシス |
| JP2003535847A (ja) * | 2000-06-02 | 2003-12-02 | スージェン・インコーポレーテッド | 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体 |
| AR032885A1 (es) | 2000-08-16 | 2003-12-03 | Actelion Pharmaceuticals Ltd | Bis-sulfonamidas, composiciones farmaceuticas, procedimiento para prepararlas y el uso de las mismas para la produccion de las composiciones farmaceuticas |
| US20040152648A1 (en) | 2001-05-23 | 2004-08-05 | Axel Ullrich | Pyruvate-kinase as a novel target molecule |
| AU2003217936A1 (en) | 2002-03-28 | 2003-10-13 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| IL165262A0 (en) * | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Kinase inhibitors |
| US7629341B2 (en) | 2002-06-12 | 2009-12-08 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
| GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| US20070032418A1 (en) | 2003-02-25 | 2007-02-08 | Ambion, Inc | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same |
| JP2005008624A (ja) * | 2003-05-27 | 2005-01-13 | Taiho Yakuhin Kogyo Kk | テトラハイドロキノリン骨格を有するスルホンアミド誘導体およびその塩 |
| WO2005074946A1 (en) | 2004-02-10 | 2005-08-18 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
| CA2556589A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| RU2261246C1 (ru) | 2004-04-15 | 2005-09-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Замещенные 7-сульфонил бензо[b][1,4]диазепины (варианты), способы их получения (варианты), фокусированная библиотека и фармацевтическая композиция |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| CA2577309C (en) | 2004-06-24 | 2013-10-22 | Temple University - Of The Commonwealth System Of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| TW200606152A (en) | 2004-07-02 | 2006-02-16 | Tanabe Seiyaku Co | Piperidine compound and process for preparing the same |
| FR2872704B1 (fr) | 2004-07-12 | 2007-11-02 | Laurent Schwartz | Pluritherapie contre le cancer |
| WO2006055880A2 (en) | 2004-11-16 | 2006-05-26 | Genzyme Corporation | Diagnostic pkm2 methods and compositions |
| WO2006087543A1 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| KR20080021030A (ko) | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| AR054363A1 (es) | 2005-05-23 | 2007-06-20 | Astrazeneca Ab | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
| FR2887881B1 (fr) * | 2005-07-01 | 2009-10-09 | Pierre Fabre Medicament Sa | Inhibiteurs de proteines kinases |
| ES2397275T3 (es) | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| EP1962851A2 (en) | 2005-12-22 | 2008-09-03 | SmithKline Beecham Corporation | Compounds |
| JP2009521444A (ja) | 2005-12-22 | 2009-06-04 | メルク エンド カムパニー インコーポレーテッド | カルシウムチャンネルブロッカーとなる置換ピペリジン |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| BRPI0706654A2 (pt) | 2006-01-20 | 2011-04-05 | Smithkline Beecham Corp | composição farmacêutica, método para tratar condições ou distìrbios em um mamìfero, uso de um composto, e, composto |
| US8987474B2 (en) * | 2006-04-07 | 2015-03-24 | University Of South Florida | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs |
| US20090325944A1 (en) * | 2006-04-12 | 2009-12-31 | Suzanne Walker Kahne | Methods and Compositions for Modulating Glycosylation |
| ATE469129T1 (de) | 2006-07-11 | 2010-06-15 | Sanofi Aventis | N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide |
| TW200817319A (en) * | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| CL2007003223A1 (es) | 2006-11-10 | 2008-01-11 | Wyeth Corp | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. |
| CA2680139A1 (en) | 2007-03-05 | 2008-09-12 | Biolipox Ab | New methylenebisphenyl compounds useful in the treatment of inflammation |
| WO2008124838A1 (en) * | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
| US7897776B2 (en) | 2007-04-23 | 2011-03-01 | Salutria Pharmaceuticals Llc | Sulfonamide containing compounds for treatment of inflammatory disorders |
| US8552050B2 (en) | 2007-08-16 | 2013-10-08 | Beth Israel Deaconess Medical Center | Activators of pyruvate kinase M2 and methods of treating disease |
| RU2522456C2 (ru) * | 2007-08-21 | 2014-07-10 | Синомикс, Инк. | Соединения, ингибирующие (блокирующие) горький вкус, способы их применения и получения |
| WO2009036341A2 (en) * | 2007-09-14 | 2009-03-19 | The Regents Of The University Of Michigan | Compositions and methods relating to hiv protease inhibition |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009084501A1 (ja) * | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
| GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| ES2620634T3 (es) * | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
-
2011
- 2011-04-26 JP JP2013508139A patent/JP2013525438A/ja active Pending
- 2011-04-26 AU AU2011245441A patent/AU2011245441B2/en not_active Expired - Fee Related
- 2011-04-26 WO PCT/US2011/033852 patent/WO2011137089A1/en not_active Ceased
- 2011-04-26 US US13/643,594 patent/US20130109672A1/en not_active Abandoned
- 2011-04-26 EP EP11730473A patent/EP2563761A1/en not_active Withdrawn
- 2011-04-26 CA CA2797694A patent/CA2797694A1/en not_active Abandoned
-
2015
- 2015-03-10 US US14/643,107 patent/US9708267B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130109672A1 (en) | 2013-05-02 |
| US20150183744A1 (en) | 2015-07-02 |
| AU2011245441B2 (en) | 2014-12-18 |
| US9708267B2 (en) | 2017-07-18 |
| AU2011245441A1 (en) | 2012-11-15 |
| WO2011137089A1 (en) | 2011-11-03 |
| JP2013525438A (ja) | 2013-06-20 |
| EP2563761A1 (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2797694A1 (en) | Activators of human pyruvate kinase | |
| JP2013525438A5 (enExample) | ||
| EA201071006A1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
| CY1112332T1 (el) | Αμινο-ετεροκυκλικες ενωσεις | |
| IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| WO2007143523A3 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| ATE517882T1 (de) | Chinolinderivate | |
| UA93872C2 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| NZ543897A (en) | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | |
| TW201002701A (en) | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | |
| MX2009008338A (es) | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. | |
| AR056155A1 (es) | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| MY144968A (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| PE20081462A1 (es) | Bifenilsulfonilos y fenil heteroaril sufonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
| CY1119787T1 (el) | Υποκατεστημενα παραγωγα 2-[2-(φαινυλ)αιθυλαμινο] αλκαναμιδιου και η χρηση αυτων ως τροποποιητων του διαυλου νατριου και/ή ασβεστιου | |
| AR074226A1 (es) | Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor. | |
| ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
| RU2005131172A (ru) | Производные хинолионона/бензоксазинона и их применение | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| RU2007116987A (ru) | Новые соединения | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160426 |
|
| FZDE | Dead |
Effective date: 20180426 |